Enfusion (ENFN) Competitors

UiPath (NYSE:PATH) and Enfusion (NYSE:ENFN) are both business services companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Do institutionals and insiders hold more shares of PATH or ENFN?

62.5% of UiPath shares are owned by institutional investors. Comparatively, 81.1% of Enfusion shares are owned by institutional investors. 22.4% of UiPath shares are owned by insiders. Comparatively, 36.4% of Enfusion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media favor PATH or ENFN?

In the previous week, UiPath had 15 more articles in the media than Enfusion. MarketBeat recorded 22 mentions for UiPath and 7 mentions for Enfusion. Enfusion's average media sentiment score of 1.31 beat UiPath's score of 0.87 indicating that Enfusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
UiPath	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Enfusion	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, PATH or ENFN?

UiPath has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Is PATH or ENFN more profitable?

Enfusion has a net margin of 1.70% compared to UiPath's net margin of -6.49%. Enfusion's return on equity of 6.67% beat UiPath's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
UiPath	-6.49%	-4.14%	-2.82%
Enfusion	1.70%	6.67%	4.86%

Does the MarketBeat Community favor PATH or ENFN?

UiPath received 120 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 38.92% of users gave UiPath an outperform vote while only 19.61% of users gave Enfusion an outperform vote.

Company	Underperform	Outperform
UiPath	Outperform Votes 130 38.92%	Underperform Votes 204 61.08%
Enfusion	Outperform Votes 10 19.61%	Underperform Votes 41 80.39%

Do analysts prefer PATH or ENFN?

UiPath currently has a consensus target price of $12.72, suggesting a potential upside of 21.83%. Enfusion has a consensus target price of $11.83, suggesting a potential upside of 9.62%. Given UiPath's higher possible upside, equities research analysts clearly believe UiPath is more favorable than Enfusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UiPath	2 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enfusion	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has stronger earnings & valuation, PATH or ENFN?

Enfusion has lower revenue, but higher earnings than UiPath. UiPath is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UiPath	$1.43B	4.03	-$89.88M	-$0.13	-80.31
Enfusion	$201.61M	6.91	$6.03M	$0.03	359.83

Summary

Enfusion beats UiPath on 11 of the 17 factors compared between the two stocks.